The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 28, 2023
Filed:
Sep. 15, 2017
Applicant:
Baylor College of Medicine, Houston, TX (US);
Inventors:
Carlos A. Ramos, Houston, TX (US);
Cliona M. Rooney, Bellaire, TX (US);
Neeharika Narala, The Woodlands, TX (US);
Assignee:
Baylor College of Medicine, Houston, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 15/00 (2006.01); C12N 5/00 (2006.01); A61K 39/12 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C12N 5/0636 (2013.01); C12N 5/0639 (2013.01); A61K 39/0011 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/80 (2018.08); A61P 35/00 (2018.01); C12N 5/0638 (2013.01); C12N 2501/02 (2013.01); C12N 2501/05 (2013.01); C12N 2501/051 (2013.01); C12N 2501/056 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2301 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/24 (2013.01); C12N 2501/25 (2013.01); C12N 2501/999 (2013.01); C12N 2502/1107 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1121 (2013.01); C12N 2710/20034 (2013.01);
Abstract
Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.